Preparation and<i> in vitro</i> studies of polysaccharide modified compound liposomes loaded with paclitaxel and doxorubicin

HAO Jingmei; WANG Hui; LI Qiong; ZHU Liang; ZHANG Yong; HUO Meirong

doi:10.11665/j.issn.1000-5048.20170608

Journal of China Pharmaceutical University > 2017 > 48(6): 680-686. > DOI: 10.11665/j.issn.1000-5048.20170608

HAO Jingmei, WANG Hui, LI Qiong, ZHU Liang, ZHANG Yong, HUO Meirong. Preparation and in vitro studies of polysaccharide modified compound liposomes loaded with paclitaxel and doxorubicin[J]. Journal of China Pharmaceutical University, 2017, 48(6): 680-686. DOI: 10.11665/j.issn.1000-5048.20170608

Citation:

PDF (1169 KB)

Preparation and in vitro studies of polysaccharide modified compound liposomes loaded with paclitaxel and doxorubicin

More Information

Graphical Abstract

Abstract

Abstract

The objectives of this study were to prepare polysaccharide modified compound liposomes loaded with paclitaxel(PTX)and doxorubicin(DOX)and characterize their phyisicochemical properties, stability and in vitro release profiles. Both PTX-DOX-Lipo and N-lauryl-O-glycol chitosan(LGC)modified liposomes(PTX-DOX-Lipo-LGC)were successfully prepared, and the morphology of the liposomes was observed by transmission electron microscope(TEM), and particle size and zeta potential were analyzed by dynamic light scattering(DLS). pH and osmotic pressure were also determined. The drug loading and encapsulation efficiency, stability and in vitro release were assayed using high-performance liquid phase. Both PTX-DOX-Lipo and PTX-DOX-Lipo-LGC exhibited spherical shape with smooth surface. The average diameter was about 150 nm. pH value and osmotic pressure were in the range of 5. 3-6. 1 and 820-870 mOsm/kg, respectively. Both PTX and DOX could be encapsulated in liposomes with high encapsulation efficiency(greater than 90%). Compared with PTX-DOX-Lipo, PTX-DOX-Lipo-LGC exhibited lower leakage, higher stability in serum and more sustained release profiles. Moreover, a quicker release rate was observed in pH 5. 8 PBS compared with pH 7. 4 PBS. PTX-DOX-Lipo-LGC with high drug loading, good stability and sustained drug release profiles has a wide prospect in future clinical application.

FullText(HTML)

References (16)

References

[1]	Ward EM,DeSantis CE,Lin CC,et al.Cancer statistics:breast cancer in situ[J].CA Cancer J Clin,2015,65(6):481-495.
[2]	Garcia G,Odaimi M.Systemic combination chemotherapy in elderly pancreatic cancer:a review[J].J Gastrointest Cancer,2017,48(2):121-128.
[3]	Kruis W,Nguyen PG,Morgenstern J.Promises and dangers of combination therapy[J].Dig Dis,2017,35(1/2):56-60.
[4]	Bakrania AK,Variya BC,Patel SS.Novel targets for paclitaxel nano formulations:hopes and hypes in triple negative breast cancer[J].Pharmacol Res,2016,111:577-591.
[5]	Agudelo D,Bourassa P,Berube G,et al.Review on the binding of anticancer drug doxorubicin with DNA and tRNA:structural models and antitumor activity[J].J Photochem Photobiol B,2016,158:274-279.
[6]	Nagao S,Nishikawa T,Hanaoka T,et al.Feasibility study of combination chemotherapy with paclitaxel,doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer[J].Jpn J Clin Oncol,2014,44(11):1040-1044.
[7]	McMeekin DS,Sill MW,Walker JL,et al.A phase I study of IV doxorubicin plus intraperitoneal(IP)paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure(GOG 9920):an NRG oncology/gynecologic oncology group study[J].Gynecol Oncol,2015,138(1):36-40.
[8]	Batist G,Gelmon KA,Chi KN,et al.Safety,pharmacokinetics,and efficacy of CPX-1 liposome injection in patients with advanced solid tumors[J].Clin Cancer Res,2009,15(2):692-700.
[9]	Cortes JE,Goldberg SL,Feldman EJ,et al.Phase II,multicenter,randomized trial of CPX-351(cytarabine:daunorubicin)liposome injection versus intensive salvage therapy in adults with first relapse AML[J].Cancer,2015,121(2):234-242.
[10]	Lancet JE,Cortes JE,Hogge DE,et al.Phase 2 trial of CPX-351,a fixed 5:1 molar ratio of cytarabine/daunorubicin,vs cytarabine/daunorubicin in older adults with untreated AML[J].Blood,2014,123(21):3239-3246.
[11]	Thao LQ,Lee C,Kim B,et al.Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma[J].Colloids Surf B Biointerfaces,2017,152:183-191.
[12]	Rui M,Xin Y,Li R,et al.Targeted biomimetic nanoparticles for synergistic combination chemotherapy of paclitaxel and doxorubicin[J].Mol Pharm,2017,14(1):107-123.
[13]	Baabur-Cohen H,Vossen LI,Kruger HR,et al.In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio[J].J Control Release,2017,257:118-131.
[14]	Sudha T,Bharali DJ,Yalcin M,et al.Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac[J].Int J Nanomedicine,2017,12:1305-1315.
[15]	Liu YR,Fang JX,Kim YJ et al.Codelivery of doxorubicin and paclitaxel by cross-linked mulitiamellar liposome enables synergistic antitumor activity[J].Mol Pharm,2014,11(5):1651-1661.
[16]	Wang YW,Zhang HY,Hao J,et al.Lung cancer combination therapy:co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect[J].Drug Deliv,2015,24:1-6.

Cited By

Get Citation

PDF

XML

Article views (741) PDF downloads (1336)

Turn off MathJax

Article Contents

Abstract

References

Preparation and in vitro studies of polysaccharide modified compound liposomes loaded with paclitaxel and doxorubicin

Abstract

References

Catalog

Export File

Citation

Format

Content